1

This work was supported by grant from Instituto de Salud Carlos III (ISCIII) (PI15/01055) and the Kidney Research Network REDINREN (RD16/0009/0025 ) of the Instituto de Salud Carlos III (ISCIII ), Spain, co-funded by FEDER

Presentación de PowerPoint · Summarizing, kidney structure is damaged after an episode of cisplatin- induced AKI although renal function seems to be recovered. Three urinary proteins

Download PDF Report

Upload
others
View
0
Download
0

Embed Size (px)

Citation preview

Page 1: Presentación de PowerPoint · Summarizing, kidney structure is damaged after an episode of cisplatin- induced AKI although renal function seems to be recovered. Three urinary proteins

This work was supported by grant from Instituto de Salud Carlos III (ISCIII) (PI15/01055) and the Kidney Research Network REDINREN (RD16/0009/0025 ) of the Institutode Salud Carlos III (ISCIII ), Spain, co-funded by FEDER

AKI - SHIRLY.ppt

AKI - SHIRLY.ppt

Documents

The AKI to CKD Continuum: a Clinical Perspective · 2019. 11. 4. · AKI: CKD Progression AKI on CKD: CKD Progression CJASN 2009. AKI is an independent risk factor for subsequent

The AKI to CKD Continuum: a Clinical Perspective · 2019. 11. 4. · AKI: CKD Progression AKI on CKD: CKD Progression CJASN 2009. AKI is an independent risk factor for subsequent

Documents

Acute Kidney Injury (AKI) Recognition and Management in ......312 studies, 152 using KDIGO-AKI, 50 million episodes Pooled AKI incidence 21.6% in adults, 33.7% in children Pooled AKI

Acute Kidney Injury (AKI) Recognition and Management in ......312 studies, 152 using KDIGO-AKI, 50 million episodes Pooled AKI incidence 21.6% in adults, 33.7% in children Pooled AKI

Documents

Documents

Cisplatin Final

Cisplatin Final

Documents

Documents

Perioperative AKI

Perioperative AKI

Documents

AKI 01 AKI Overview

AKI 01 AKI Overview

Documents

PODER EJECUTIVO SISTEMA PARA EL …...AKI- 8276 MAY CAN FELIPA AKI- 8331 MAY DOMINGUEZ RAMONA AKI- 8369 MAY MELECIO AKI- 8488 MAY PECH MIGUEL ANGEL AKI- 8505 MAY NAH ANACLETO AKI-

PODER EJECUTIVO SISTEMA PARA EL …...AKI- 8276 MAY CAN FELIPA AKI- 8331 MAY DOMINGUEZ RAMONA AKI- 8369 MAY MELECIO AKI- 8488 MAY PECH MIGUEL ANGEL AKI- 8505 MAY NAH ANACLETO AKI-

Documents

Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and … · cisplatin stock solution used for culturing CP.5 cells was prepared in PBS. The cisplatin-resistant

Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and … · cisplatin stock solution used for culturing CP.5 cells was prepared in PBS. The cisplatin-resistant

Documents

Sourced from CKD Management in General Practice (3rd ... · AKI management plan How to prevent AKI How to diagnose AKI What to do during an AKI episode What to do after an AKI episode

Sourced from CKD Management in General Practice (3rd ... · AKI management plan How to prevent AKI How to diagnose AKI What to do during an AKI episode What to do after an AKI episode

Documents

Targeting colorectal cancer cell metabolism through ......Determination of cisplatin levels After treating HCT-116 cells with cisplatin, cisplatin nano-cubosomes and cisplatin-metformin

Targeting colorectal cancer cell metabolism through ......Determination of cisplatin levels After treating HCT-116 cells with cisplatin, cisplatin nano-cubosomes and cisplatin-metformin

Documents

Presentación de PowerPoint - forodebateoncologia.net · Options for first-line cisplatin-eligible patients Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin

Presentación de PowerPoint - forodebateoncologia.net · Options for first-line cisplatin-eligible patients Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin

Documents

Colon Oral Cisplatin

Colon Oral Cisplatin

Documents

Health & Medicine

Ameliorative Effect of Sesamin in Cisplatin-Induced ... · in cancer patients that leads to acute kidney injury (AKI), followed by chronic renal problems (Latcha . 2016, et al Skinner

Ameliorative Effect of Sesamin in Cisplatin-Induced ... · in cancer patients that leads to acute kidney injury (AKI), followed by chronic renal problems (Latcha . 2016, et al Skinner

Documents

Documents

An Introduction to Acute Kidney Injury (AKI) - Home - · PDF file · 2015-10-07An Introduction to Acute Kidney Injury (AKI) ... •An AKI case study •Monitoring and assessing AKI

An Introduction to Acute Kidney Injury (AKI) - Home - · PDF file · 2015-10-07An Introduction to Acute Kidney Injury (AKI) ... •An AKI case study •Monitoring and assessing AKI

Documents

Acute Kidney Injury Board Review. AKI Basics of AKI New Biomarkers of renal injury Pathogenesis of AKI Treatment of AKI Clinical questions based learning

Acute Kidney Injury Board Review. AKI Basics of AKI New Biomarkers of renal injury Pathogenesis of AKI Treatment of AKI Clinical questions based learning

Documents

Concurrent Weekly Cisplatin Versus Triweekly Cisplatin ...journal.waocp.org/article_26843_900ad9a447487d8d2cde6de76a53a25a.pdfWeekly Versus Triweekly Cisplatin with Radiotherapy for

Concurrent Weekly Cisplatin Versus Triweekly Cisplatin ...journal.waocp.org/article_26843_900ad9a447487d8d2cde6de76a53a25a.pdfWeekly Versus Triweekly Cisplatin with Radiotherapy for

Documents

Pathogenesis of AKI AKI - Echo360 › media › ASN14BRCU_15 › ... · to contribute to mechanisms by which AKI leads to CKD. Pathogenesis of AKI: Key Points: Update • Role of

Pathogenesis of AKI AKI - Echo360 › media › ASN14BRCU_15 › ... · to contribute to mechanisms by which AKI leads to CKD. Pathogenesis of AKI: Key Points: Update • Role of

Documents

Aminoglycoside- and Cisplatin-Induced Ototoxicity

Aminoglycoside- and Cisplatin-Induced Ototoxicity

Documents

Cisplatin: mode of cytotoxic action and molecular basis of ...home.sandiego.edu/~josephprovost/cisplatin review.pdf · Cisplatin: mode of cytotoxic action and molecular basis of resistance

Cisplatin: mode of cytotoxic action and molecular basis of ...home.sandiego.edu/~josephprovost/cisplatin review.pdf · Cisplatin: mode of cytotoxic action and molecular basis of resistance

Documents

AKI Definitions

AKI Definitions

Documents

Documents

Documents

Documents

Review Cisplatin

Review Cisplatin

Documents

Review Cisplatin and Nanotechnology

Review Cisplatin and Nanotechnology

Documents

CERVICAL CANCER: SYSTEMIC TREATMENT...Cisplatin + topotecan 9.4 4.6 27 GOG-0204 (2009)3 513 Cisplatin + paclitaxel 12.9 5.8 29 Study consolidated cisplatin-paclitaxel as SoC No other

CERVICAL CANCER: SYSTEMIC TREATMENT...Cisplatin + topotecan 9.4 4.6 27 GOG-0204 (2009)3 513 Cisplatin + paclitaxel 12.9 5.8 29 Study consolidated cisplatin-paclitaxel as SoC No other

Documents